Study analysis · Circulation · 2019
A blood marker of heart stress at 60 predicted weaker grip at 69 — but the difference was only 0.63 kg, about 1.17 years of normal aging.
In 1,736 British adults, higher midlife NT-proBNP and IL-6 were linked to slightly weaker grip, slower walking, and worse balance 9 years later, but the study is observational and doesn't report absolute disability risk.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study followed a large group of people for about nine years and found that certain blood markers were linked to weaker grip, slower walking, and worse balance later on. It shows a connection, but it cannot prove that the blood markers cause the physical decline. We can say they are associated, not that one causes the other.
What’s the bottom line?
Researchers followed 1,736 British adults from age 60–64 to age 69. They measured blood markers of heart/kidney stress and inflammation. Higher NT-proBNP and IL-6 were linked to weaker grip, slower walking and chair rises, and worse balance 9 years later.
How strong is this study?
The study is strong because it followed many people for a long time and used fair, objective tests, and it tried to account for many other factors. But because people were not randomly assigned to have high or low markers, hidden differences could still explain the link. So we can trust the association, but not a cause-and-effect conclusion.
75 / 100
- COI disclosure+40/40
- Data availability+35/35
- Code availabilitycode not shared
38 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control groupno control group
- Sample size (n=1736)+20/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 567 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. Observational cohort design without randomization or control group; associations may be confounded by unmeasured factors, reverse causation, and residual confounding. Temporal sequence is present but does not prove causation.
No Conflicts
No conflicts of interest identified
No conflicts of interest identified. The study appears to be an independent analysis of a publicly funded birth cohort.
The provided text does not include a conflict of interest or funding statement. The study uses data from the MRC National Survey of Health and Development, a publicly funded birth cohort. No industry involvement is apparent.
Key takeaways
- 01
A 1-SD higher NT-proBNP was linked to an absolute grip strength difference of 0.63 kg weaker (95% CI −0.99 to −0.28 kg).
- 02
IL-6 was linked to 0.76 kg weaker grip (95% CI −1.11 to −0.41 kg).
- 03
Cystatin C was linked to 0.60 kg weaker grip, but not independently after full adjustment.
- 04
E-selectin was not linked.
- 05
The NT-proBNP grip difference is about equal to 1.17 years of normal age-related grip decline.
- 06
In absolute terms, the grip strength difference is small: about 0.63 kg weaker grip per 1-SD higher NT-proBNP, roughly equal to 1.17 years of normal age-related grip loss.
- 07
The study did not report absolute risk of disability or disease (e.g., extra cases per 1,000 people), so that remains unknown.
- 08
These are observational associations, not proof that the biomarkers cause decline.
Surprising findings
- NT-proBNP association was about 5 times as strong as smoking status.Smoking is a well-established risk factor, so a single blood marker outperforming it is counterintuitive.
- Associations not explained by new-onset cardiovascular disease, kidney disease, or diabetes.You'd expect chronic disease to mediate the link; instead it persisted.
- Cystatin C was not independently associated after full adjustment.It was initially linked to weaker grip, so its disappearance suggests confounding by disease/risk factors.
- E-selectin added no predictive value.Vascular endothelial activation marker didn't predict decline beyond other biomarkers.
- NT-proBNP and chair rise speed association only in men.Sex-specific effect not hypothesized; may be type I error.
Practical takeaways
Don't rush to get NT-proBNP tested for fitness.
Observational; no absolute disability risk; not a screening test for physical decline.
low confidenceIf you smoke, quitting remains important.
Smoking was still linked to slower chair rise and walking speed, even if biomarkers were stronger in this study.
medium confidenceTrack your physical capability in midlife.
Grip, walking, balance decline gradually; two measures only in study.
medium confidenceAsk your doctor about NT-proBNP only in clinical context.
NT-proBNP is used for heart failure diagnosis, not physical capability screening.
low confidenceFocus on modifiable risk factors: blood pressure, cholesterol, blood sugar, smoking.
In fully adjusted models, few conventional risk factors remained associated, but overall healthy aging advice stands.
medium confidenceWhy this study matters
NT-proBNP and IL-6 predict physical capability
A 1-SD higher logged NT-proBNP was associated with an ABSOLUTE grip strength difference of −0.63 kg (95% CI −0.99 to −0.28). IL-6 was associated with −0.76 kg (95% CI −1.11 to −0.41). Both also linked to slower chair rise, slower walking, and shorter balance.
Simple blood markers in midlife might flag risk of physical decline years later.
Biomarkers beat conventional risk factors
After mutual adjustment, NT-proBNP and IL-6 were more strongly associated with physical capability than pulse pressure, cholesterol ratio, HbA1c, and smoking. The NT-proBNP association was about 5 times as strong as smoking status (relative comparison of effect estimates, not risk).
We usually blame smoking and cholesterol for aging, but these biomarkers may be more informative.
Not explained by new disease
Adjusting for new-onset cardiovascular disease, kidney disease, or diabetes at age 69 did not attenuate the associations. Excluding participants with these diseases also didn't change results.
Suggests the biomarkers aren't just marking diagnosed disease.
Cystatin C fades; E-selectin fails
Cystatin C initially linked to weaker grip (−0.60 kg, 95% CI −0.94 to −0.25) but was no longer independent after full adjustment. E-selectin was not independently associated with any outcome after mutual adjustment.
Not all biomarkers are equal; some are just proxies for disease.
Sex difference for chair rise
The inverse association between NT-proBNP and slower chair rise speed was apparent only in men (P for interaction = 0.002). No consistent sex interaction for other outcomes.
Aging may differ by sex, but this could be chance.
Corrections and observational limits
The study has published corrections/errata. It's observational, with only two serial physical capability measures, and absolute risk of disability was not reported.
Headlines may overstate; the effect is small and causality unproven.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Researchers followed 1,736 British adults from age 60–64 to age 69. They measured blood markers of heart/kidney stress and inflammation. Higher NT-proBNP and IL-6 were linked to weaker grip, slower walking and chair rises, and worse balance 9 years later.
Research results
A 1-SD higher NT-proBNP was linked to an absolute grip strength difference of 0.63 kg weaker (95% CI −0.99 to −0.28 kg). IL-6 was linked to 0.76 kg weaker grip (95% CI −1.11 to −0.41 kg). Cystatin C was linked to 0.60 kg weaker grip, but not independently after full adjustment. E-selectin was not linked. The NT-proBNP grip difference is about equal to 1.17 years of normal age-related grip decline.
What this means - more context
In absolute terms, the grip strength difference is small: about 0.63 kg weaker grip per 1-SD higher NT-proBNP, roughly equal to 1.17 years of normal age-related grip loss. The study did not report absolute risk of disability or disease (e.g., extra cases per 1,000 people), so that remains unknown. These are observational associations, not proof that the biomarkers cause decline.
Investigated whether midlife biomarkers of heart and kidney damage/stress and systemic inflammation predict level and decline in physical capability over 9 years in a British birth cohort.
Note: This study has published corrections/errata; readers should check the correction notices for updated information. In 1,736 British adults aged 60–64 at baseline, higher midlife NT-proBNP and IL-6 were associated with poorer physical capability 9 years later, including weaker grip strength, slower chair rise and walking speeds, and shorter standing balance. For example, a 1-SD higher logged NT-proBNP was associated with an absolute grip strength difference of −0.63 kg (95% CI −0.99 to −0.28), and IL-6 with −0.76 kg (95% CI −1.11 to −0.41). Cystatin C was associated with weaker grip but not independent after full adjustment; E-selectin was not independently associated. Associations were not explained by new-onset cardiovascular disease, kidney disease, or diabetes.
Methods Used
Prospective cohort study using MRC NSHD, the oldest British birth cohort. 1,736 men and women with physical capability measures (grip strength, chair rise speed, walking speed, standing balance) at ages 60–64 and 69. Biomarkers (cystatin C, NT-proBNP, IL-6, E-selectin) measured at age 60–64; models adjusted for sex, height, BMI, baseline performance, mutual biomarkers, cardiovascular risk factors, disease status, and lifetime socioeconomic position.
Main Finding
Higher midlife NT-proBNP and IL-6 were associated with poorer physical capability 9 years later. Absolute grip strength differences per 1-SD higher logged biomarker: NT-proBNP −0.63 kg (95% CI −0.99 to −0.28); IL-6 −0.76 kg (95% CI −1.11 to −0.41); cystatin C −0.60 kg (95% CI −0.94 to −0.25), but cystatin C attenuated after full adjustment. The NT-proBNP grip strength difference corresponds to approximately 1.17 years of age-related grip strength decline. Absolute risk of disability or incident disease was not reported.
Confidence Level
Moderate to high for observational evidence: large well-characterized birth cohort, 9-year follow-up, objective physical measures, extensive adjustment. Causal inference limited by observational design, only two serial physical capability measures, possible residual confounding, and published corrections/errata.
Study Flags
Red Flags
- •Corrections/errata published; readers should check correction notices for updated information.
- •Observational design: residual confounding and reverse causation possible; cannot prove causation.
- •Only two serial physical capability measures, limiting ability to assess change; absolute risk of disability not reported.
Surprising Findings
NT-proBNP association was about 5 times as strong as smoking status.
Smoking is a well-established risk factor, so a single blood marker outperforming it is counterintuitive.
Practical Takeaways
Don't rush to get NT-proBNP tested for fitness.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 567 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study followed a large group of people for about nine years and found that certain blood markers were linked to weaker grip, slower walking, and worse balance later on. It shows a connection, but it cannot prove that the blood markers cause the physical decline. We can say they are associated, not that one causes the other.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Large population-based birth cohort with long follow-up
- Objective measures of physical capability
- Repeated assessments at ages 60-64 and 69
Weaknesses
- Observational design precludes causal inference
- No randomization or control group
- Potential residual confounding
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Researchers followed 1,736 British adults from age 60–64 to age 69. They measured blood markers of heart/kidney stress and inflammation. Higher NT-proBNP and IL-6 were linked to weaker grip, slower walking and chair rises, and worse balance 9 years later.
Research results
A 1-SD higher NT-proBNP was linked to an absolute grip strength difference of 0.63 kg weaker (95% CI −0.99 to −0.28 kg). IL-6 was linked to 0.76 kg weaker grip (95% CI −1.11 to −0.41 kg). Cystatin C was linked to 0.60 kg weaker grip, but not independently after full adjustment. E-selectin was not linked. The NT-proBNP grip difference is about equal to 1.17 years of normal age-related grip decline.
What this means - more context
In absolute terms, the grip strength difference is small: about 0.63 kg weaker grip per 1-SD higher NT-proBNP, roughly equal to 1.17 years of normal age-related grip loss. The study did not report absolute risk of disability or disease (e.g., extra cases per 1,000 people), so that remains unknown. These are observational associations, not proof that the biomarkers cause decline.
Investigated whether midlife biomarkers of heart and kidney damage/stress and systemic inflammation predict level and decline in physical capability over 9 years in a British birth cohort.
Note: This study has published corrections/errata; readers should check the correction notices for updated information. In 1,736 British adults aged 60–64 at baseline, higher midlife NT-proBNP and IL-6 were associated with poorer physical capability 9 years later, including weaker grip strength, slower chair rise and walking speeds, and shorter standing balance. For example, a 1-SD higher logged NT-proBNP was associated with an absolute grip strength difference of −0.63 kg (95% CI −0.99 to −0.28), and IL-6 with −0.76 kg (95% CI −1.11 to −0.41). Cystatin C was associated with weaker grip but not independent after full adjustment; E-selectin was not independently associated. Associations were not explained by new-onset cardiovascular disease, kidney disease, or diabetes.
Methods Used
Prospective cohort study using MRC NSHD, the oldest British birth cohort. 1,736 men and women with physical capability measures (grip strength, chair rise speed, walking speed, standing balance) at ages 60–64 and 69. Biomarkers (cystatin C, NT-proBNP, IL-6, E-selectin) measured at age 60–64; models adjusted for sex, height, BMI, baseline performance, mutual biomarkers, cardiovascular risk factors, disease status, and lifetime socioeconomic position.
Main Finding
Higher midlife NT-proBNP and IL-6 were associated with poorer physical capability 9 years later. Absolute grip strength differences per 1-SD higher logged biomarker: NT-proBNP −0.63 kg (95% CI −0.99 to −0.28); IL-6 −0.76 kg (95% CI −1.11 to −0.41); cystatin C −0.60 kg (95% CI −0.94 to −0.25), but cystatin C attenuated after full adjustment. The NT-proBNP grip strength difference corresponds to approximately 1.17 years of age-related grip strength decline. Absolute risk of disability or incident disease was not reported.
Confidence Level
Moderate to high for observational evidence: large well-characterized birth cohort, 9-year follow-up, objective physical measures, extensive adjustment. Causal inference limited by observational design, only two serial physical capability measures, possible residual confounding, and published corrections/errata.
Study Flags
Red Flags
- •Corrections/errata published; readers should check correction notices for updated information.
- •Observational design: residual confounding and reverse causation possible; cannot prove causation.
- •Only two serial physical capability measures, limiting ability to assess change; absolute risk of disability not reported.
Surprising Findings
NT-proBNP association was about 5 times as strong as smoking status.
Smoking is a well-established risk factor, so a single blood marker outperforming it is counterintuitive.
Practical Takeaways
Don't rush to get NT-proBNP tested for fitness.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 567 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study followed a large group of people for about nine years and found that certain blood markers were linked to weaker grip, slower walking, and worse balance later on. It shows a connection, but it cannot prove that the blood markers cause the physical decline. We can say they are associated, not that one causes the other.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Large population-based birth cohort with long follow-up
- Objective measures of physical capability
- Repeated assessments at ages 60-64 and 69
Weaknesses
- Observational design precludes causal inference
- No randomization or control group
- Potential residual confounding
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study is strong because it followed many people for a long time and used fair, objective tests, and it tried to account for many other factors. But because people were not randomly assigned to have high or low markers, hidden differences could still explain the link. So we can trust the association, but not a cause-and-effect conclusion.
75 / 100
- COI disclosure+40/40
- Data availability+35/35
- Code availabilitycode not shared
38 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control groupno control group
- Sample size (n=1736)+20/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 567 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. Observational cohort design without randomization or control group; associations may be confounded by unmeasured factors, reverse causation, and residual confounding. Temporal sequence is present but does not prove causation.
No Conflicts
No conflicts of interest identified
No conflicts of interest identified. The study appears to be an independent analysis of a publicly funded birth cohort.
The provided text does not include a conflict of interest or funding statement. The study uses data from the MRC National Survey of Health and Development, a publicly funded birth cohort. No industry involvement is apparent.
Standing
The people behind it
The researchers who wrote the study this analysis is built on.
Authored by
6 researchersIf this is your work, this is how we attribute it on Fit Body Science. Diana Kuh is listed as the lead author.